secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0001493152-25-006875
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports Q2 FY2025 net loss $2.5M ($0.09/sh); secures $15M private placement; FDA supports pediatric plan
--------------------------------------------------------------------------------

- Net loss for Q2 FY2025 (Dec 31, 2024) was $2.5M, or $0.09 per share, compared to $2.7M ($0.11) in prior year.
- Cash and equivalents $15.0M as of Dec 31, 2024; additional $3M available under amended loan.
- FDA acknowledged unmet need for pediatric cannabis toxicity treatment; Phase 1 SAD study of IV selonabant expected in H1 2025.
- Closed $15M private placement with 22NW Fund, issuing 15.2M shares.
- Amended loan with 22NW and JFL, reducing max to $3M and removing securitization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225006875/0001493152-25-006875-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225006875/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-006875

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer